2026-04-17T05:38:58Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1927422025-12-04T21:44:47Zcom_2072_1057col_2072_478917col_2072_478933
RECERCAT
author
Spinelli, Guglielmo
author
Caballero Hernández, Ana Belén
author
Gámez Enamorado, Patrick
2023-01-27T12:01:29Z2023-01-27T12:01:29Z2022-12-212023-01-27T12:01:29Z
Photodynamic therapy (PDT) uses a combination of molecular oxygen, light and a photosensitizer (PS) to generate singlet oxygen or reactive oxygen species (ROS), which can eradicate tumoral cells. All currently approved PSs for cancer treatment are molecular PSs. To date, no nanoparticlebased PSs are used clinically although it has widely been shown that nanotechnology may help to improve the properties of molecular PSs; for instance, molecular PSs suffer from some intrinsic limitations that undermine their therapeutic efficacy. In the present minireview, the most critical weaknesses exhibited by molecular PSs are described, and the potential use of nanoparticles (NPs) to address them and to reach the clinics is discussed.
cc-by-nc (c) Spinelli, Guglielmo et al., 2022 https://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess
Càncer
Nanociència
Cancer
Nanoscience
Nanotechnological approaches to address photosensitizers' limitations: towards improved clinical applicability of photodynamic therapy
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion